Log in

NASDAQ:SYRSSyros Pharmaceuticals Stock Price, Forecast & News

-0.48 (-3.84 %)
(As of 08/12/2020 04:00 PM ET)
Today's Range
Now: $12.01
50-Day Range
MA: $11.27
52-Week Range
Now: $12.01
Volume139,600 shs
Average Volume298,604 shs
Market Capitalization$549.60 million
P/E RatioN/A
Dividend YieldN/A
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Read More
Syros Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SYRS



Sales & Book Value

Annual Sales$1.98 million
Book Value$1.87 per share


Net Income$-75,440,000.00
Net Margins-1,114.79%


Market Cap$549.60 million
Next Earnings Date11/10/2020 (Estimated)
-0.48 (-3.84 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

How has Syros Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SYRS shares have increased by 133.2% and is now trading at $12.01.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Syros Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Syros Pharmaceuticals

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Syros Pharmaceuticals

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its earnings results on Thursday, August, 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.02. Syros Pharmaceuticals had a negative net margin of 1,114.79% and a negative return on equity of 88.63%.
View Syros Pharmaceuticals' earnings history

What price target have analysts set for SYRS?

6 equities research analysts have issued twelve-month price targets for Syros Pharmaceuticals' shares. Their forecasts range from $9.00 to $20.00. On average, they expect Syros Pharmaceuticals' stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals

Has Syros Pharmaceuticals been receiving favorable news coverage?

News articles about SYRS stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Syros Pharmaceuticals earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Syros Pharmaceuticals

Are investors shorting Syros Pharmaceuticals?

Syros Pharmaceuticals saw a decline in short interest in July. As of July 31st, there was short interest totaling 2,940,000 shares, a decline of 7.8% from the July 15th total of 3,190,000 shares. Based on an average daily volume of 357,100 shares, the days-to-cover ratio is currently 8.2 days. Approximately 8.4% of the company's shares are short sold.
View Syros Pharmaceuticals' Short Interest

Who are some of Syros Pharmaceuticals' key competitors?

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Amicus Therapeutics (FOLD), Advanced Micro Devices (AMD), ImmunoGen (IMGN), Amarin (AMRN), Immunomedics (IMMU), Nektar Therapeutics (NKTR) and Pfizer (PFE).

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)
  • Dr. David A. Roth, Chief Medical Officer (Age 56)
  • Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)
  • Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (10.34%), Arch Venture Corp (0.87%), Bank of New York Mellon Corp (0.33%), California Public Employees Retirement System (0.21%), Goldman Sachs Group Inc. (0.14%) and Alps Advisors Inc. (0.14%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Jeremy P Springhorn, Mark J Alles, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch.
View institutional ownership trends for Syros Pharmaceuticals

Which institutional investors are selling Syros Pharmaceuticals stock?

SYRS stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Sumitomo Mitsui Trust Holdings Inc., State of Wisconsin Investment Board, and UBS Group AG. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Eric R Olson, Richard A Young, and Srinivas Akkaraju.
View insider buying and selling activity for Syros Pharmaceuticals

Which institutional investors are buying Syros Pharmaceuticals stock?

SYRS stock was acquired by a variety of institutional investors in the last quarter, including Alps Advisors Inc., California Public Employees Retirement System, Bessemer Group Inc., Virtus ETF Advisers LLC, Bank of New York Mellon Corp, State Board of Administration of Florida Retirement System, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., and Goldman Sachs Group Inc.. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, Mark J Alles, and Srinivas Akkaraju.
View insider buying and selling activity for Syros Pharmaceuticals

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $12.01.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $549.60 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.